Pharming Group (PHAR) Stock Statistics & Valuation Metrics

Pharming Group has a market cap or net worth of $929.55M. The enterprise value is $744.24M.

Pharming Group has 68,514,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pharming Group’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -3.35%.

The current PE Ratio of Pharming Group is ―. Pharming Group’s PEG ratio is ―.

In the last 12 months, Pharming Group had revenue of 297.20M and earned -10.64M in profits. Earnings per share was -0.15.

In the last 12 months, operating cash flow was 31.72M and capital expenditures -913.99K, giving a free cash flow of 30.80M billion.

Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―

Pharming Group upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).

Pharming Group as a current ratio of 3.77, with Debt / Equity ratio of 53.57%

In the past 12 months, Pharming Group has paid 2.43M in taxes.

Pharming Group EV to EBITDA ratio is 414.07, with an EV/FCF ratio of -2.61K.

Pharming Group has $128.73M in cash and marketable securities with $128.33M in debt, giving a net cash position of -$408.00K billion.

Gross margin is 89.31%, with operating margin of -2.90%, and net profit margin of -3.58%.

The average price target for Pharming Group is $30.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy